<DOC>
	<DOCNO>NCT01018693</DOCNO>
	<brief_summary>The purpose study determine whether VAK694 combine subcutaneous immunotherapy lead long term immune tolerance allergen individual seasonal allergic rhinitis .</brief_summary>
	<brief_title>A Study Determine Capacity VAK694 When Combined With Allergen Immunotherapy Bring About Specific Immune Tolerance</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<criteria>History atopy , define history seasonal allergic rhinitis least 2 year ( relation grass pollen allergy season ) , evidence atopy , define positive skin prick test ( wheal difference allergen negative control least 3 mm ) grass pollen allergen screen . Male female subject age 18 60 year ( inclusive ) Female subject must nonchildbearing potential Subjects must weigh least 50 kg body mass index ( BMI ) within range 18 32 kg/m2 ( inclusive ) Informed consent Treatment intranasal corticosteroid within 28 day prior first dose . History asthma treatment inhale systemic corticosteroid within 6 month first dose . History COPD . Any exposure human monoclonal polyclonal antibody . Any allergy immunotherapy within 3 year prior screen . Any prior grass pollen allergy immunotherapy . FEV1 &lt; 70 % predict screening baseline . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Seasonal allergic rhinitis ,</keyword>
	<keyword>late phase response ,</keyword>
	<keyword>alutard avanz ,</keyword>
	<keyword>immunotherapy ,</keyword>
	<keyword>visual analogue scale ,</keyword>
	<keyword>mini rhinitis quality life ,</keyword>
	<keyword>immune modulation</keyword>
</DOC>